Insights

Gathering insights about IMT…

Similar companies to IMT

IMT Tech Stack

IMT uses 8 technology products and services including W3 Total Cache, WordPress, oEmbed, and more. Explore IMT's tech stack below.

W3 Total Cache
Caching
WordPress
Content Management System
oEmbed
Dev Tools
jQuery
Javascript Libraries
SweetAlert
Javascript Libraries
jQuery Migrate
Javascript Libraries
PHP
Programming Languages
Yoast SEO
Search Engines

Media & News

Immatics: PRAME Is Becoming More Than A Single-Asset Story
Immatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just a single-asset cell therapy play. IMTX's lead asset, anzu-cel, is in Phase 3 for advanced melanoma, but broader value lies in its layered PRAME franchise and pipeline expansion. IMTX maintains a strong cash runway into 2028, enabling critical clinical milestones without distressed financing or near-term capital risk.
Jun 16, 2026 | seekingalpha.com
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany , June 1, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced extended data from the ongoing Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203) PRAME TCR T-cell therapy in heavily pretreated patients with advanced melanoma in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, USA. The dataset is focused on patients treated with anzu-cel at the recommended Phase 2 dose (RP2D), including longer follow-up and further characterization of the durability and systemic nature of the observed clinical responses.
Jun 01, 2026 | www.globenewswire.com
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal melanomaAnzu-cel showed a 56% confirmed ORR, 14. 6 months mDOR, 6. 1 months mPFS and 16. 2 months mOS at longer follow-up alongside a predictable and manageable tolerability profile in metastatic melanoma Exploratory response analysis suggests continued control of baseline disease and anti-tumor activity across multiple metastatic disease sites with many lesions remaining controlled, some even after progressionFindings reinforce the continued effectiveness of anzu-cel to treat advanced melanoma; Phase 3 SUPRAME trial remains on track as it advances toward BLA submission in 1H 2027 Houston, Texas and Tuebingen, Germany, June 1, 2026 - Immatics N.
Jun 01, 2026 | www.globenewswire.com
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR of 8.
May 31, 2026 | www.globenewswire.com
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Houston, Texas and Tuebingen , Germany, May 31, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific (TCER®) candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. The data show a consistent and favorable tolerability profile across multiple tumor types and encouraging anti-tumor activity at the recommended Phase 2 dose (RP2D) with or without the immune checkpoint inhibitor (ICI) pembrolizumab. Results from the Phase 1 study are being published simultaneously in Nature Medicine .
May 31, 2026 | www.globenewswire.com
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective response rate (ORR), 50% confirmed ORR (cORR), including four complete responses, and longest ongoing response at 12 months Additional Phase 1 data for IMA203CD8 in heavily pretreated patients with synovial sarcoma showed deep and durable responses with a 67% ORR and 64% cORR, including one complete response, and ongoing responses up to ~3 years IMA203CD8 demonstrated a manageable and consistent tolerability profile across patient populations Clinical anti-tumor activity observed across tumor types (ovarian carcinoma, uterine cancer, melanoma, synovial sarcoma) with distinct biology and differing levels of PRAME expression, including lower PRAME levels in ovarian carcinoma Clinical profile of IMA203CD8 supports continued development in gynecologic cancers and expansion into other PRAME-positive solid tumors Determination of recommended phase 2 dose (RP2D) remains expected in 2026 Houston, Texas and Tuebingen, Germany, May 30, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA.
May 30, 2026 | www.globenewswire.com
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.35 per share a year ago.
May 12, 2026 | www.zacks.com

IMT's Email Address Formats

IMT uses at least 1 format(s):

IMT Email Formats	Example	Percentage
First@imagemusictext.com	John@imagemusictext.com	100%

Frequently Asked Questions

Where is IMT's headquarters located?

IMT's main headquarters is located at 210 Cambridge Heath Road Unit 2 London, England e2 9nq United Kingdom. The company has employees across 1 continents, including Europe.

What is IMT's stock symbol?

IMT is a publicly traded company; the company's stock symbol is IMTX.

What is IMT's official website and social media links?

IMT's official website is imagemusictext.com and has social profiles on LinkedIn.

What is IMT's SIC code NAICS code?

IMT's SIC code is 5999 - Miscellaneous Retail Stores, Not Elsewhere Classified NAICS code is 7115 - Independent Artists, Writers, and Performers.

How many employees does IMT have currently?

As of May 2026, IMT has approximately 8 employees across 1 continents, including Europe. Key team members include Director: L. A. F.Artist: L. R. K. S.. Explore IMT's employee directory with LeadIQ.

What industry does IMT belong to?

IMT operates in the Artists and Writers industry.

What technology does IMT use?

IMT's tech stack includes W3 Total CacheWordPressoEmbedjQuerySweetAlertjQuery MigratePHPYoast SEO.

What is IMT's email format?

IMT's email format typically follows the pattern of First@imagemusictext.com. Find more IMT email formats with LeadIQ.

When was IMT founded?

IMT was founded in 2005.

IMT

Q: What is IMT's official website and social media links?

IMT's official website is imagemusictext.com. IMT has social profiles on LinkedIn.

Q: How many employees does IMT have currently?

IMT has approximately 8 employees.

Q: What technology does IMT use?

IMT's tech stack includes Twemoji, jQuery, WordPress Super Cache, Google Analytics, Google Fonts API.

Q: What is IMT's NAICS code?

IMT's NAICS code is 7115 (Independent Artists, Writers, and Performers).

Artists and WritersEngland, United Kingdom2-10 Employees

IMT is a London-based contemporary art gallery that runs a free public programme of critical, innovative art commissions, exhibitions, and events. It represents a focused group of artists, including David Burrows, Plastique Fantastique, and Maggie Roberts. The gallery has presented a range of multimedia installations and group shows, often produced in collaboration with other institutions or spaces. The gallery operates with a small team in London and runs a program that connects artists with audiences through its projects. Several exhibitions and commissions have involved partnerships with organizations such as Castlefield Gallery and Forma, and some projects have been supported by Arts Council England.

Company Overview

Headquarters: 210 Cambridge Heath Road Unit 2 London, England e2 9nq United Kingdom
Website: imagemusictext.com
SIC Code: 5999 - Miscellaneous Retail Stores, Not Elsewhere Classified
Stock Symbol: IMTX
NAICS Code: 7115 - Independent Artists, Writers, and Performers
Founded: 2005
Employees: 2-10

Media & News

Funding & Financials

$1M
IMT's revenue is estimated to be in the range of $1M

Funding & Financials

$1M
IMT's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to IMT

STRATAFOLIO

BoldTrail BackOffice (The Next Gen of Brokermint)

VTS

Buildout

SharpLaunch

Apto

Aptys Solutions

Ascendix Technologies

LightBox | ClientLook

CommissionTrac (Acquired by Yardi)

IMT Tech Stack

Media & News

Immatics: PRAME Is Becoming More Than A Single-Asset Story

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates

IMT's Email Address Formats

Frequently Asked Questions

Where is IMT's headquarters located?

What is IMT's stock symbol?

What is IMT's official website and social media links?

What is IMT's SIC code NAICS code?

How many employees does IMT have currently?

What industry does IMT belong to?

What technology does IMT use?

What is IMT's email format?

When was IMT founded?

IMT

Company Overview

Media & News

Immatics: PRAME Is Becoming More Than A Single-Asset Story

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?